Clinical Trial Results: LYT-100 in Post-acute COVID-19 Respiratory Disease [Phase 2]

View source ↗

Summary

Phase 2 trial results for LYT-100 in post-acute COVID-19 respiratory disease have been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute COVID-19 Respiratory Disease

Drugs mentioned

• LYT-100

Snippet

Sponsor: PureTech | Conditions: Covid19, Post-acute COVID-19 Respiratory Disease | Phase 2 | Status: TERMINATED | Results posted: 2026-06-23